0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Case Report/Case Series |

Vemurafenib and Radiosensitization

Lise Boussemart, MD1; Catherine Boivin, MD2; Joël Claveau, MD2; Yun Gan Tao, MD3; Gorana Tomasic, MD4; Emilie Routier, MD1; Christine Mateus, MD1; Eric Deutsch, MD, PhD3; Caroline Robert, MD, PhD1
[+] Author Affiliations
1Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
2Department of Dermatology, Melanoma and Skin Cancer Clinic, Centre hospitalier universitaire de Québec—Hôpital Hôtel-Dieu, Quebec City, Quebec, Canada
3Department of Radiation Oncology (Drs Tao and Deutsch), Institut Gustave Roussy, Villejuif, France
4Department of Pathology, Institut Gustave Roussy, Villejuif, France
JAMA Dermatol. 2013;149(7):855-857. doi:10.1001/jamadermatol.2013.4200.
Text Size: A A A
Published online

Importance  The BRAF inhibitor, vemurafenib, was recently approved for the treatment of patients with BRAFV600 metastatic melanoma. Wider use of this drug and longer follow-up periods of treatment are resulting in the emergence of a growing number of reports detailing new adverse effects. Cutaneous adverse effects are preeminent with UV-A–dependent phototoxicity, hyperkeratotic folliculitis, hand-foot skin reaction, hair changes, verrucous papillomas, keratoacanthomas, and squamous cell carcinomas.

Observations  We report 2 cases of dermatitis occurring on a previously irradiated skin area in patients treated with vemurafenib for a BRAFV600-mutated metastatic melanoma. The first case occurred 10 days after a low dose of radiation was delivered that usually does not induce any radiodermatitis, suggesting radiosensitization by vemurafenib. The second case occurred 30 days after radiotherapy and was diagnosed as radiation recall dermatitis.

Conclusions and Relevance  Vemurafenib should be considered a potential cutaneous radiosensitizer and an inducer of radiation recall dermatitis. However, these adverse effects are easily managed with topical corticosteroids. Dose reduction or interruption of vemurafenib is not required. Further studies and reports will enlighten us as to whether this pharmacodynamic interaction between x-rays and vemurafenib is also seen with other BRAF or MEK inhibitors on the same mitogen-activated protein kinase pathway currently under development.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Place holder to copy figure label and caption
Figure 1.
Vesicular Erythematous Dermatitis

Vesicular erythematous dermatitis strictly located around the right shoulder skin metastasis in patient 1.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Skin Biopsy Specimen

Skin biopsy specimen from the dermatitis observed around the previously irradiated skin metastasis in patient 1 (hematoxylin and eosin, ×5 [A] and ×10 [B]).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Sharply Delimited Rectangular Eczematous Plaque

Sharply delimited rectangular eczematous plaque on the buttock in patient 2, exactly matching the previously irradiated field.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 4

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Vemurafenib and radiosensitization. JAMA Dermatol 2013;149(7):855-7.
[Radiosensitization induced by vemurafenib]. Cancer Radiother 2013 Jul-Aug;17(4):304-7.
Jobs
brightcove.createExperiences();